Lif: Legislative change paves the way for new supply solutions in Denmark

13 May 2024

An amendment to the Medicines Act, which entered into force on January 1, 2024, already now gives the Danish Medicines Agency the opportunity to, on its own initiative, allow the sale or supply of medicines without a Danish marketing authorization from abroad in the event of a supply failure.

The Danish Medicines Agency has just published how the agency will concretely administer and inform about the scheme.

Alongside the new scheme, doctors, dentists and vets can still apply if they would like to use a foreign medicine to replace a medicine they cannot get in Denmark. The Pharmaceutical Industry Association, Lif, welcomes the initiative:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK